Trinity Biotech plc
TRIB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $11 | $8 | $16 | $15 |
| % Growth | 44.8% | -52.2% | 4.7% | – |
| Cost of Goods Sold | $7 | $6 | $11 | $10 |
| Gross Profit | $4 | $2 | $5 | $5 |
| % Margin | 39.5% | 20.7% | 30.8% | 35% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $7 | $5 | $8 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $7 | $0 |
| Operating Expenses | $7 | $6 | $16 | $8 |
| Operating Income | -$3 | -$5 | -$12 | -$3 |
| % Margin | -27.7% | -62.5% | -72.6% | -16.9% |
| Other Income/Exp. Net | -$3 | -$4 | -$4 | -$2 |
| Pre-Tax Income | -$6 | -$9 | -$16 | -$5 |
| Tax Expense | $0 | $0 | $1 | -$0 |
| Net Income | -$6 | -$9 | -$17 | -$5 |
| % Margin | -55.1% | -116.2% | -106.9% | -31.4% |
| EPS | -0.32 | -0.48 | -1.2 | -0.46 |
| % Growth | 33.3% | 60% | -160.9% | – |
| EPS Diluted | -0.32 | -0.48 | -1.2 | -0.46 |
| Weighted Avg Shares Out | 19 | 18 | 14 | 10 |
| Weighted Avg Shares Out Dil | 19 | 18 | 14 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $2 | $2 | $4 | $3 |
| Depreciation & Amortization | $1 | $1 | $0 | $1 |
| EBITDA | -$3 | -$6 | -$10 | -$1 |
| % Margin | -26.7% | -77.2% | -60.5% | -7.3% |